- Blinded evaluation study with leading global IVD player
demonstrated diagnostic performance in line with FDA requirements
for antibiotic susceptibility testing (AST)
- Already received orders for more than1,000 molecular AST tests
offered under the brand name ARESupa – Universal Pathogenome
Assay
- Total contractual order volume received in 2019 for
next-generation sequencing tests as well as advanced
bioinformatics, AI services and certain rights amounts to over EUR
2 million
Vienna, Austria, and Holzgerlingen,
Germany, October 28, 2019, 08:00 am CET - Curetis N.V.
(the "Company" and, together with its
subsidiaries, "Curetis"), a developer of next-level molecular
diagnostic solutions, today announced that its fully-owned
subsidiary Ares Genetics has launched an early access program for
its novel, artificial intelligence (AI) powered, next-generation
sequencing (NGS) based molecular antibiotic susceptibility test
(AST).
Information on antibiotic susceptibility of
pathogens is of utmost importance for clinical practice,
epidemiology and public health purposes as well as for the
development of pharmaceutical products in the infectious disease
sector. Ares Genetics therefore has developed a molecular AST that
will be marketed under the brand name ARESupa – Universal
Pathogenome Assay. It is an expanded version of the NGS-based
ARESupa initially launched in August 2019 for the identification of
pathogens and resistance genes. The new version of the ARESupa is
now capable of also accurately predicting antibiotic susceptibility
via AI-powered interpretation of high-throughput DNA sequencing
data.
ARESupa is based on whole-genome sequencing of
bacterial strains isolated from clinical specimens, combined with
data analysis and interpretation powered by ARESdb, Ares Genetics’
unique, proprietary reference database on genetic antimicrobial
resistance markers. ARESdb covers genomes of about 40,000 bacterial
strains and associated susceptibility data for more than 100
different antibiotics.
Already, Ares Genetics has received commercial
orders for more than 1,000 ARESupa tests, an order volume exceeding
EUR 500,000. Together with advanced bioinformatics and AI services
leveraging ARESdb for the diagnostics and pharma industry, as well
as access to certain rights, Ares Genetics has contracted for and
received orders amounting to more than EUR 2 million in 2019 to
date.
A blinded evaluation study with a leading global
IVD player recently demonstrated a predictive performance of the
AI-powered ARESupa in line with FDA requirements for over 50
drug/pathogen combinations. Further blinded evaluation studies with
leading academic medical centers are anticipated for Q4/2019.
With the early access program gaining momentum,
broader commercialization of the AI-powered antibiotic
susceptibility test is anticipated to begin in early 2020. The test
will be initially offered for non-diagnostic applications in
epidemiology, infection control, and outbreak analysis for
customers in the public health sector and the pharmaceutical
industry. A laboratory-developed test (LDT) on native patient
samples for human diagnostic use in indications in which current
culture-based diagnostic practice is inherently challenging is
planned. Furthermore, Ares Genetics has recently entered into a
multi-phase strategic partnership with an undisclosed leading
global in vitro diagnostics corporation to jointly develop
diagnostic solutions for infectious disease testing based on the
ARESupa.
Ares Genetics’ R&D programs for the
development of ARESupa are co-funded by non-dilutive public grants
provided by the Vienna Business Agency, the Austrian Research
Promotion Agency (FFG), and other institutions with a total
co-funded volume of up to more than EUR 3 million. In addition to
the ARESupa, Ares Genetics provides advanced bioinformatics and AI
services to customers in the pharmaceutical industry and in public
health, and in September 2019, QIAGEN, in a strategic partnership
and under a license from Ares Genetics, launched ARESdb as part of
its CLC Microbial Genomics Module for general explorative
antibiotic research by the life science community.
Ares Genetics, which recently was recognized as
a leading AI start-up in the DACH region by Forbes
(https://www.forbesdach.com/artikel/top-30-start-ups-aus-dem-dach-raum.html),
has been invited to present its AI-powered approach to molecular
AST at various scientific and public health conferences in
Q4/2019:
EIT Health German-French Bilateral Meeting 4-5 November,
Mannheim, Germany
European Summit of Industrial Biotechnology 18-20 November,
Graz, Austria
3rd Congress Immunotherapies & Innovations for Infectious
Diseases 3-4 December, Lyon, France
13. Nationaler Qualitätskongress Gesundheit, 12-13 December,
Berlin, Germany
###
ARESupa Universal Pathogenome
AssayFor further information and quotes, please register
on the Ares Genetics cloud platform:https://ares-genetics.cloud/or
contactAres Genetics GmbH Karl-Farkas-Gasse 18 A-1030 Wien
AustriaEmail: services@ares-genetics.com About
Curetis
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH is developing next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to
buy nor to subscribe securities and neither this document nor any
part of it should form the basis of any investment decision in
Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements”. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes”,
“estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or
“should”, and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact Details
Curetis GmbHMax-Eyth-Str.
4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10pr@curetis.com
or ir@curetis.comwww.curetis.com
Curetis International Media &
Investor InquiriesakampionDr. Ludger Wess / Ines-Regina
Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel.
+49 30 23 63 27 68
- 20191028_PR_Curetis_ARESupa_FINAL_APPROVED-1
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
